Key Metrics of Neurogene Inc.
Revenue$0FY 2023
Operating income−$55.6M▲ 1.7% YoY
Net profit−$36.3M▲ 34.2% YoY
Shareholders' equity$186M
Market cap$577MNGNE · $28.82
Competitors10identified
About Neurogene Inc.
Sectors
Company details
- Founded
- 2014
- Listed
- Nasdaq: NGNE (since 2014)
Operational Areas of Neurogene Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameNeurogene Inc.
TickerNGNE
ExchangeNasdaq
CountryCanada
SEC CIK0001404644
Listed since2014
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
NGNE · Nasdaq · SEC CIK 0001404644
Last price · 31 Oct 2026
$28.82
−5.26%
Market cap$577M
P/E—On FY 2023 diluted EPS
Volume310,014
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOCanadaListed 2014
NGNE share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Neurogene Inc.
Competitors10identified
Countries3most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Global IT Services & Consulting · IT Services & Software | retisoft.com | — | Canada | |
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.